Clinical trial
Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult…
NCT00363454 · Prescient Therapeutics, Ltd., Industry · Completed
Key facts
| NCT number | NCT00363454 |
|---|---|
| Title | Phase I Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer |
| Official title | Phase I Pharmacokinetic and Pharmacodynamic, Open-Label, Dose Escalation Study of Triciribine Phosphate Monohydrate (TCN-PM, VD-0002) in Adult Subjects With Metastatic Cancer Which Have Activated Akt Demonstrated by Immunohistochemistry |
| Lead sponsor | Prescient Therapeutics, Ltd., Industry |
| Collaborators | VioQuest Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Triciribine Phosphate Monohydrate |
| Enrollment | 19 |
| Start date | Apr 1, 2006 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | Aug 15, 2006 |
| Last update posted | Aug 9, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: